LCTX
HEALTHCARELineage Cell Therapeutics Inc
AI Insight
What's Moving LCTX Today?
No stock-specific AI insight has been generated for LCTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.85$2.09
$1.28
Fundamentals
Market Cap$312M
P/E Ratio—
EPS$-0.29
Dividend Yield—
Dividend / Share—
ROE-98.2%
Profit Margin—
Debt / Equity—
Trading
Volume406K
Avg Volume (10D)—
Shares Outstanding249.3M
LCTX News
21 articles- Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh CoverageYahoo Finance·Jun 18, 2026
- How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst TargetsYahoo Finance·Jun 4, 2026
- Promising Penny Stocks To Consider In May 2026Yahoo Finance·May 26, 2026
- Lineage Cell Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 15, 2026
- Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·May 13, 2026
- Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 12, 2026
- Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 12, 2026
- Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue EstimatesYahoo Finance·May 11, 2026
- Guardant Health (GH) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026Yahoo Finance·May 5, 2026
- OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026Yahoo Finance·May 4, 2026
- Niagen Bioscience And 2 Additional Promising Penny Stocks For Your ConsiderationYahoo Finance·Apr 15, 2026
- Lineage Announces Formation of Scientific Advisory BoardYahoo Finance·Apr 13, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
- Lineage Cell (LCTX) Launches Its Latest Cell Therapy ProgramYahoo Finance·Mar 31, 2026
- Lineage Launches New Cell Therapy Program in Corneal Endothelial DiseaseYahoo Finance·Mar 24, 2026
- Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- Lineage Cell Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Lineage Cell (LCTX) Reports Break-Even Earnings for Q4Yahoo Finance·Mar 5, 2026
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 5, 2026
- Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 3, 2026
All 21 articles loaded
Price Data
Open$1.25
Previous Close$1.25
Day High$1.28
Day Low$1.25
52 Week High$2.09
52 Week Low$0.85
52-Week Range
$0.85$2.09
$1.28
Fundamentals
Market Cap$312M
P/E Ratio—
EPS$-0.29
Dividend Yield—
Dividend / Share—
ROE-98.2%
Profit Margin—
Debt / Equity—
Trading
Volume406K
Avg Volume (10D)—
Shares Outstanding249.3M
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—